Cyclopharm Presents at the 2025 Bell Potter Healthcare Conference

Cyclopharm was pleased to participate in the Bell Potter Healthcare Conference on November 19th, where CEO & Managing Director James McBrayer outlined the company’s accelerating global momentum, including the continued rollout of Technegas in the United States.

The presentation highlighted several key developments shaping the next phase of growth:

• US commercial expansion is gaining pace, with 40 revenue-generating sites and a strong pipeline supported by national reimbursement and an expanded sales force. Installation guidance of 250–300 US sites in 2H 2026 was reaffirmed.
• Technegas continues to strengthen its role as the ventilation imaging agent of choice, with more than 5 million patient procedures performed globally and adoption across 66 countries.
• Clinical evidence remains a significant driver, with SPECT V/Q imaging consistently outperforming CTPA across multiple diagnostic measures (page 29) and growing utilisation “Beyond PE,” including COPD, asthma, and lung cancer applications (pages 37–40).
• The company maintained a record growth trajectory, with revenue up 26% in 1H 2025 and the US now nearing a top global ranking for consumables (pages 23 & 15).

As respiratory medicine continues to evolve, Cyclopharm’s unique drug-device-service model positions Technegas to support clinicians with more accurate, lower-radiation, and patient-friendly pulmonary imaging solutions.

For more insights, the full presentation is available on our website.